Stenoparib is under clinical development by Allarity Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Stenoparib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Stenoparib (E-7449) is under development for the treatment of solid tumors, including triple negative breast cancer, metastatic ovarian cancer, metastatic breast cancer, melanoma, B-cell malignancies including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma, follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma, pancreatic cancer, lung cancer, mesothelioma, coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through oral route as a capsule. It acts by targeting PARP 1 and 2 and Tankyrase 1 and 2.
It was also under development for endometrial cancer, and pediatric tumors including neuroblastoma, sarcoma, renal tumors.
Allarity Therapeutics overview
Allarity Therapeutics (Allarity) is a precision medicine company that develops drugs for cancer. The company is investigating Dovitinib, a pan-tyrosine kinase inhibitor targeting RCC (renal cell cancer), gastrointestinal stromal tumor (GIST), liver, metastatic breast, and endometrial cancer; and Stenoparib, a dual PARP and Tankyrase inhibitor against ovarian cancer. It is also evaluating Ixempra (ixabepilone), a cell-cycle specific antimicrotubule agent; and LiPlaCis, a target controlled liposome formulation to treat metastatic breast cancer; and 2X-111 targeting glioblastoma multiform (GBM) and brain metastases of breast cancer (mBC). Allarity utilizes its proprietary drug response predictor (DRP) diagnostic platform technology that models human tumor biology and predicts cancer patient response. The company has operational presence in Hoersholm, Denmark. Allarity is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Stenoparib’s drug-specific PTSR and LoA scores, buy the report here.